GLP-1s and the Gut Microbiome: What the Research Actually Shows (2025 Review)

Written By Rosa Keller

Everyone is talking about GLP-1 medications and appetite regulation.
Almost no one is talking about what they’re doing to the gut microbiome.

A 2025 systematic review published in Nutrients (Gofron et al., 38 studies across animal and human data) provides a more complex picture than what is commonly shared in the wellness space.

The findings are not straightforward.

GLP-1s and Positive Microbiome Changes

Across multiple GLP-1 receptor agonists, including liraglutide, exenatide, dulaglutide, and semaglutide, one pattern appears consistently.

Akkermansia muciniphila increases across most studies.

This species is associated with:

  • Gut barrier integrity

  • Metabolic health

  • Lean metabolic profiles

Other observed changes in several studies include:

  • Increased Bifidobacterium

  • Increased Lactobacillus in some liraglutide trials

  • Decreased LPS-producing bacteria such as Klebsiella, suggesting reduced inflammatory potential

Microbial Diversity: Inconsistent Findings

The evidence on overall microbial diversity is inconsistent.

Alpha diversity results vary across studies:

  • Some animal studies show increases

  • Some show decreases

  • Several human liraglutide trials show no significant change

For semaglutide:

  • Akkermansia increases

  • But overall diversity decreases in some models

This makes interpretation less clear than commonly presented online.

Firmicutes to Bacteroidetes Ratio

The Firmicutes to Bacteroidetes ratio is often used as a simplified marker of gut health, but results in GLP-1 studies are inconsistent.

Findings include:

  • No change in some studies

  • Increase in others

  • Metabolic improvement still occurring despite these shifts

This suggests the ratio alone is not a reliable marker of metabolic outcomes.

Clinical Interpretation

GLP-1 medications should not be viewed as direct microbiome enhancers.

They function more as a biological perturbation.

What happens next depends on:

  • Baseline microbiome composition

  • Dietary patterns, especially fiber intake

  • Use of other medications such as metformin

  • Duration of therapy

  • Overall metabolic health

A reduction in alpha diversity is not inherently negative, but it also does not guarantee a resilient gut ecosystem.
Context is essential.

👉 For a deeper clinical nutrition strategy during GLP-1 therapy, see:
GLP-1 Nutrition Support for Health, Energy, and Muscle Preservation

Key Takeaway

Diet remains the primary determinant of microbiome stability.

Regardless of GLP-1 use, supporting gut health requires:

  • High fiber intake

  • Plant-rich dietary patterns

  • Nutrient-dense whole foods

  • Adequate protein intake

  • Dietary diversity

GLP-1 medications may shift microbial composition, but long-term gut health is largely shaped by nutrition and lifestyle.

Personalized Support for GLP-1 and Gut Health

GLP-1 medications can significantly influence appetite, metabolism, and the gut microbiome. However, outcomes vary based on diet, baseline health, and lifestyle factors.

A personalized nutrition approach can help support:

  • Gut microbiome balance during GLP-1 therapy

  • Lean muscle and metabolic function

  • Energy levels and long-term health outcomes

  • Reduction of potential side effects through dietary optimization

If you are currently using GLP-1 medication or considering it, structured nutritional guidance can make a measurable difference.

👉 Book a Personalized Consultation With Rosa Keller

Reference

Gofron et al. (2025). Nutrients, 17(8):1303. PMID: 40284168

Rosa Keller
Next

Meal Timing for Cardiometabolic Health